WT1
WT1 (Wilms tumour protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Mesothelioma, Myeloproliferative neoplasms and 5 more.
Overview
Transcription factor that plays an important role in cellular development and cell survival. Recognises and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'. Regulates the expression of numerous target genes, including EPO.
CIViC holds 12 clinical evidence items and 0 assertions across 3 variants, naming Daunorubicin and Cytarabine. Open Targets scores its association with cancer at 0.90 (direct and indirect evidence; datatypes clinical 0.63, genetic literature 0.90, affected pathway 0.36, literature 1.00, genetic association 0.91, somatic mutation 0.89, animal model 0.68). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Acute Myeloid Leukaemia, Melanoma, Pancreatic Adenocarcinoma. In OnCo, 1 product record names it (INO-5401).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · WT1 (Wilms tumour protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Mesothelioma, Myeloproliferative neoplasms and 5 more.
- 1 · What it is
WT1 (Wilms tumour protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Mesothelioma, Myeloproliferative neoplasms and 5 more.
- 2 · What goes wrong in cancer
Transcription factor that plays an important role in cellular development and cell survival. Recognises and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'.
- 3 · How drugs use it
No product in this corpus aims at WT1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:12796 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P19544 (protein name, function text, keywords and locations (REST API)); CIViC gene WT1 (12 evidence items, 0 assertions, 3 variants; diseases: Acute Myeloid Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000184937 (association with cancer (MONDO_0004992) 0.90; per-cancer scores at or above 0.5: sarcoma 0.59, malignant mesothelioma 0.69, acute myeloid leukaemia 0.65, acute lymphoblastic leukaemia 0.56, non-Hodgkin lymphoma 0.60, myeloproliferative neoplasm 0.68 (GraphQL API, CC0)); IntOGen WT1 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcription factor that plays an important role in cellular development and cell survival. Recognises and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'. Regulates the expression of numerous target genes, including EPO. Plays an essential role for development of the urogenital system. It has a tumour suppressor as well as an oncogenic role in tumour formation. Function may be isoform-specific: isoforms lacking the KTS motif may act as transcription factors. Location: Nucleus; Nucleus, nucleolus; Cytoplasm; Nucleus speckle (UniProt). Locus 11p13 (HGNC).
- Leukaemia: Open Targets association 0.72 with leukaemia (MONDO_0005059)
- Mesothelioma: Open Targets association 0.69 with malignant mesothelioma (MONDO_0006292)
- Myeloproliferative neoplasms: Open Targets association 0.68 with myeloproliferative neoplasm (MONDO_0020076)
- Non-Hodgkin lymphoma: Open Targets association 0.60 with non-Hodgkin lymphoma (MONDO_0018908)
- Sarcomas: Open Targets association 0.59 with sarcoma (MONDO_0005089)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.63; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; CIViC holds 12 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"WT1" OR ABSTRACT:"WT1" OR TITLE:"WT1 transcription factor" OR ABSTRACT:"WT1 transcription factor" OR TITLE:"Wilms tumor protein" OR ABSTRACT:"Wilms tumor protein" OR TITLE:"WIT-2" OR ABSTRACT:"WIT-2" OR TITLE:"AWT1" OR ABSTRACT:"AWT1" OR TITLE:"NPHS4" OR ABSTRACT:"NPHS4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about WT1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZRSR2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetCSF2RB
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Sarcomas (soft tissue, bone, GIST), CIViC.
- TargetSH2B3
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST).
- TargetETV6
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), Sarcomas (soft tissue, bone, GIST).
- TargetPOLD1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetSRSF2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), CIViC.
- TargetPRKCD
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Non-Hodgkin lymphoma (all types), Acute myeloid leukaemia.
- TargetCEBPA
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.